Enliven Therapeutics, Inc.
ELVNNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ELVN. That does not mean none is planned.
Get an email about ELVN's next catalysts
Track Enliven Therapeutics (ELVN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ELVN-001 | Phase 3 | Chronic Myeloid Leukemia (CML) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Enliven Therapeutics, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Enliven Therapeutics, Inc.'s (ELVN) pipeline across Phase 3. Its lead program is ELVN-001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Enliven Therapeutics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Enliven Therapeutics, Inc. (ELVN) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ELVN biotech catalysts?β
Add ELVN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Enliven Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
